Moreover, a phase 1b trial found that the CCR2 antagonist in combination with the FOLFIRINOX chemotherapy was safe and tolerable in the treatment of pancreatic cancer, which resulted in an endogenous anti-tumor environment (18). The gene discussed is CCR2; the disease is neoplasm.